Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver

Xing Fang, Tatsuo Nunoshiba, Midori Yoshida, Akiyoshi Nishikawa, Kiyomitsu Nemoto, Masakuni Degawa, Sakae Arimoto, Keinosuke Okamoto, Eizo Takahashi, Tomoe Negishi

Research output: Contribution to journalArticle

Abstract

It remains uncertain why non-genotoxic compounds that result in liver hypertrophy cause liver tumors. In an effort to resolve this issue, we examined whether liver postmitochondrial fraction (S9) prepared from rats treated with non-genotoxic compounds affected the genotoxicity of pro-mutagens. Known hepatotoxic compounds, such as piperonyl butoxide (PBO), decabromodiphenyl ether (DBDE), beta-naphthoflavone (BNF), indole-3-carbinol (I3C) and acetaminophen (AA),were orally administered to male and female F344 rats at doses sufficient to cause liver hypertrophy. Rats received diets containing each test compound for 3 days, 4 weeks or 13 weeks, and were then kept for 4 weeks without the test chemical. S9 prepared from the livers of each group was used for the Ames test with 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), benzo[a]pyrene (BaP) and N-nitrosodimethylamine (NDMA). In both sexes, liver hypertrophy was observed following administration of all test compounds, and was then reversed to the control state when administration ceased. The mutagenicity of MeIQx, BaP and NDMA increased with the use of S9 derived from rats treated with non-genotoxic compounds other than AA. DBDE administration had a marked effect on the mutagenicity of BaP (over a 30-fold increase in females) and NDMA (about a 20-fold increase in males). To estimate the involvement of metabolic enzymes in the alteration of mutagenicity, we measured the activity of ethoxyresorufin-O-deethylase (EROD) and methoxyresorufin-O-demethylase (MROD) (phase I enzymes), and UDP-glucuronosyltransferase (UGT) and glutathione S-transferase (GST) (phase II enzymes) in each S9 sample. The activity of phase I enzymes increased, even at the 3rd day following administration, and then decreased gradually, except in the case of AA, while the activity of phase II enzymes increased slightly. These results suggest that non-genotoxic hepato-hypertrophic compounds may be partly involved in carcinogenesis by modulating the metabolism of pre-carcinogens incorporated from the environment, in a manner that is dependent on sex and pre-incorporated chemicals.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalGenes and Environment
Volume36
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Oral Administration
decabromobiphenyl ether
enzyme
mutagenicity
Dimethylnitrosamine
Liver
Acetaminophen
Hypertrophy
Enzymes
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
ether
fold
Piperonyl Butoxide
beta-Naphthoflavone
genotoxicity
carcinogen
Glucuronosyltransferase
Cytochrome P-450 CYP1A1
pyrene
tumor

Keywords

  • Ames test
  • Liver hypertrophic compound
  • Metabolism
  • Mutation

ASJC Scopus subject areas

  • Genetics
  • Environmental Science (miscellaneous)
  • Social Psychology

Cite this

Fang, X., Nunoshiba, T., Yoshida, M., Nishikawa, A., Nemoto, K., Degawa, M., ... Negishi, T. (2014). Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver. Genes and Environment, 36(1), 1-9. https://doi.org/10.3123/jemsge.2013.011

Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver. / Fang, Xing; Nunoshiba, Tatsuo; Yoshida, Midori; Nishikawa, Akiyoshi; Nemoto, Kiyomitsu; Degawa, Masakuni; Arimoto, Sakae; Okamoto, Keinosuke; Takahashi, Eizo; Negishi, Tomoe.

In: Genes and Environment, Vol. 36, No. 1, 2014, p. 1-9.

Research output: Contribution to journalArticle

Fang, Xing ; Nunoshiba, Tatsuo ; Yoshida, Midori ; Nishikawa, Akiyoshi ; Nemoto, Kiyomitsu ; Degawa, Masakuni ; Arimoto, Sakae ; Okamoto, Keinosuke ; Takahashi, Eizo ; Negishi, Tomoe. / Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver. In: Genes and Environment. 2014 ; Vol. 36, No. 1. pp. 1-9.
@article{ba8c73ac35d842598e18bcb385fc652e,
title = "Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver",
abstract = "It remains uncertain why non-genotoxic compounds that result in liver hypertrophy cause liver tumors. In an effort to resolve this issue, we examined whether liver postmitochondrial fraction (S9) prepared from rats treated with non-genotoxic compounds affected the genotoxicity of pro-mutagens. Known hepatotoxic compounds, such as piperonyl butoxide (PBO), decabromodiphenyl ether (DBDE), beta-naphthoflavone (BNF), indole-3-carbinol (I3C) and acetaminophen (AA),were orally administered to male and female F344 rats at doses sufficient to cause liver hypertrophy. Rats received diets containing each test compound for 3 days, 4 weeks or 13 weeks, and were then kept for 4 weeks without the test chemical. S9 prepared from the livers of each group was used for the Ames test with 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), benzo[a]pyrene (BaP) and N-nitrosodimethylamine (NDMA). In both sexes, liver hypertrophy was observed following administration of all test compounds, and was then reversed to the control state when administration ceased. The mutagenicity of MeIQx, BaP and NDMA increased with the use of S9 derived from rats treated with non-genotoxic compounds other than AA. DBDE administration had a marked effect on the mutagenicity of BaP (over a 30-fold increase in females) and NDMA (about a 20-fold increase in males). To estimate the involvement of metabolic enzymes in the alteration of mutagenicity, we measured the activity of ethoxyresorufin-O-deethylase (EROD) and methoxyresorufin-O-demethylase (MROD) (phase I enzymes), and UDP-glucuronosyltransferase (UGT) and glutathione S-transferase (GST) (phase II enzymes) in each S9 sample. The activity of phase I enzymes increased, even at the 3rd day following administration, and then decreased gradually, except in the case of AA, while the activity of phase II enzymes increased slightly. These results suggest that non-genotoxic hepato-hypertrophic compounds may be partly involved in carcinogenesis by modulating the metabolism of pre-carcinogens incorporated from the environment, in a manner that is dependent on sex and pre-incorporated chemicals.",
keywords = "Ames test, Liver hypertrophic compound, Metabolism, Mutation",
author = "Xing Fang and Tatsuo Nunoshiba and Midori Yoshida and Akiyoshi Nishikawa and Kiyomitsu Nemoto and Masakuni Degawa and Sakae Arimoto and Keinosuke Okamoto and Eizo Takahashi and Tomoe Negishi",
year = "2014",
doi = "10.3123/jemsge.2013.011",
language = "English",
volume = "36",
pages = "1--9",
journal = "Genes and Environment",
issn = "1880-7046",
publisher = "The Japanese Environmental Mutagen Society",
number = "1",

}

TY - JOUR

T1 - Effects of oral administration of non-genotoxic hepato-hypertrophic compounds on metabolic potency of rat liver

AU - Fang, Xing

AU - Nunoshiba, Tatsuo

AU - Yoshida, Midori

AU - Nishikawa, Akiyoshi

AU - Nemoto, Kiyomitsu

AU - Degawa, Masakuni

AU - Arimoto, Sakae

AU - Okamoto, Keinosuke

AU - Takahashi, Eizo

AU - Negishi, Tomoe

PY - 2014

Y1 - 2014

N2 - It remains uncertain why non-genotoxic compounds that result in liver hypertrophy cause liver tumors. In an effort to resolve this issue, we examined whether liver postmitochondrial fraction (S9) prepared from rats treated with non-genotoxic compounds affected the genotoxicity of pro-mutagens. Known hepatotoxic compounds, such as piperonyl butoxide (PBO), decabromodiphenyl ether (DBDE), beta-naphthoflavone (BNF), indole-3-carbinol (I3C) and acetaminophen (AA),were orally administered to male and female F344 rats at doses sufficient to cause liver hypertrophy. Rats received diets containing each test compound for 3 days, 4 weeks or 13 weeks, and were then kept for 4 weeks without the test chemical. S9 prepared from the livers of each group was used for the Ames test with 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), benzo[a]pyrene (BaP) and N-nitrosodimethylamine (NDMA). In both sexes, liver hypertrophy was observed following administration of all test compounds, and was then reversed to the control state when administration ceased. The mutagenicity of MeIQx, BaP and NDMA increased with the use of S9 derived from rats treated with non-genotoxic compounds other than AA. DBDE administration had a marked effect on the mutagenicity of BaP (over a 30-fold increase in females) and NDMA (about a 20-fold increase in males). To estimate the involvement of metabolic enzymes in the alteration of mutagenicity, we measured the activity of ethoxyresorufin-O-deethylase (EROD) and methoxyresorufin-O-demethylase (MROD) (phase I enzymes), and UDP-glucuronosyltransferase (UGT) and glutathione S-transferase (GST) (phase II enzymes) in each S9 sample. The activity of phase I enzymes increased, even at the 3rd day following administration, and then decreased gradually, except in the case of AA, while the activity of phase II enzymes increased slightly. These results suggest that non-genotoxic hepato-hypertrophic compounds may be partly involved in carcinogenesis by modulating the metabolism of pre-carcinogens incorporated from the environment, in a manner that is dependent on sex and pre-incorporated chemicals.

AB - It remains uncertain why non-genotoxic compounds that result in liver hypertrophy cause liver tumors. In an effort to resolve this issue, we examined whether liver postmitochondrial fraction (S9) prepared from rats treated with non-genotoxic compounds affected the genotoxicity of pro-mutagens. Known hepatotoxic compounds, such as piperonyl butoxide (PBO), decabromodiphenyl ether (DBDE), beta-naphthoflavone (BNF), indole-3-carbinol (I3C) and acetaminophen (AA),were orally administered to male and female F344 rats at doses sufficient to cause liver hypertrophy. Rats received diets containing each test compound for 3 days, 4 weeks or 13 weeks, and were then kept for 4 weeks without the test chemical. S9 prepared from the livers of each group was used for the Ames test with 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), benzo[a]pyrene (BaP) and N-nitrosodimethylamine (NDMA). In both sexes, liver hypertrophy was observed following administration of all test compounds, and was then reversed to the control state when administration ceased. The mutagenicity of MeIQx, BaP and NDMA increased with the use of S9 derived from rats treated with non-genotoxic compounds other than AA. DBDE administration had a marked effect on the mutagenicity of BaP (over a 30-fold increase in females) and NDMA (about a 20-fold increase in males). To estimate the involvement of metabolic enzymes in the alteration of mutagenicity, we measured the activity of ethoxyresorufin-O-deethylase (EROD) and methoxyresorufin-O-demethylase (MROD) (phase I enzymes), and UDP-glucuronosyltransferase (UGT) and glutathione S-transferase (GST) (phase II enzymes) in each S9 sample. The activity of phase I enzymes increased, even at the 3rd day following administration, and then decreased gradually, except in the case of AA, while the activity of phase II enzymes increased slightly. These results suggest that non-genotoxic hepato-hypertrophic compounds may be partly involved in carcinogenesis by modulating the metabolism of pre-carcinogens incorporated from the environment, in a manner that is dependent on sex and pre-incorporated chemicals.

KW - Ames test

KW - Liver hypertrophic compound

KW - Metabolism

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=84897727342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897727342&partnerID=8YFLogxK

U2 - 10.3123/jemsge.2013.011

DO - 10.3123/jemsge.2013.011

M3 - Article

VL - 36

SP - 1

EP - 9

JO - Genes and Environment

JF - Genes and Environment

SN - 1880-7046

IS - 1

ER -